Skip to main content
Ad Scientiam

News

Come meet us

Conference

ECTRIMS 2026 — Multiple sclerosis & NMOSD

Oct 21 – 23, 2026
Toronto — Canada

Ad Scientiam presents four communications at the ECTRIMS congress (10th Joint ACTRIMS-ECTRIMS Meeting), covering MSCopilot® in multiple sclerosis (MS-DETECT and MS-FLOWER studies) and NMOSDCopilot in NMOSD (OPTIS study).

  • Poster — “Real-world movement-related MSCopilot® digital biomarkers correlate with EDSS in the MS-DETECT study”
  • Poster — “Patient-reported MS-related physical impact associated with MSCopilot® digital biomarkers in the MS-DETECT study”
  • Poster — “The OPTIS study for clinical validation of NMOSDCopilot, a software as a medical device for remote monitoring of NMOSD manifestations”
  • Communication — “Pathway to integrate MSCopilot® into Multiple Sclerosis clinical care: MS-FLOWER, a U.S. Multicenter Pilot Study”
Conference

SIN 2026 — Multiple sclerosis

Oct 24 – 27, 2026
Florence — Italy

Ad Scientiam presents two communications at the 56th Congress of the Società Italiana di Neurologia (SIN), focused on MSCopilot® digital biomarkers in multiple sclerosis (MS-DETECT study).

  • Communication — “Patient-reported MS-related physical impact associated with MSCopilot® digital biomarkers in the MS-DETECT study”
  • Communication — “Real-world movement-related MSCopilot® digital biomarkers correlate negatively with EDSS in the MS-DETECT study”

Our latest publications

Find all our latest news, press releases and scientific publications.

Press release

First Patient In for the HARMONY 360 study

Press releaseMyasthenia

Ad Scientiam announces a critical milestone with the enrollment of the First Patient In in the HARMONY 360 study

We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.

October 8, 2026

Press release

MSCopilot® interim results at EAN 2026

Press releaseMSCopilot

Ad Scientiam unveils positive 1-year interim longitudinal results for MSCopilot® at EAN 2026

At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.

June 29, 2026

Scientific publication

4 scientific posters at AAN 2026

Scientific publicationAAN

Ad Scientiam at AAN 2026: 4 scientific posters to anchor digital biomarkers in neurological practice

In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.

April 18, 2026

Press release

Ad Scientiam expands to the US

Press releaseMSCopilot

Ad Scientiam officially establishes presence in the United States

We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.

April 16, 2026

Scientific publication

MuCopilot® at JSM 2025

Scientific publicationMuCopilot

JSM 2025 — MuCopilot®: optimizing cystic fibrosis monitoring through digital biomarkers

At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.

March 9, 2026

Scientific publication

MSCopilot® biomarkers and clinical assessments

Scientific publicationMS-DETECT

MSCopilot® biomarkers reflect traditional clinical assessments

In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.

December 5, 2025

Accelerate your clinical studies and improve the monitoring of your patients

Talk to our experts and discover how our solutions integrate into your practice or studies.

Ad Scientiam

Digital Village, 21-23 Rue Albert Bayet, 75013 Paris

contact@adscientiam.com

Contact us